1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Cardiovascular Devices Market Trends
  5. > Drug Eluting Stents (DES) - Pipeline Review, 2015

Drug Eluting Stents (DES) - Pipeline Review, 2015

  • March 2015
  • -
  • Global Data
  • -
  • 210 pages

Drug Eluting Stents (DES) - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Drug Eluting Stents (DES) - Pipeline Review, 2015" provides an overview of Drug Eluting Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key drug eluting stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Drug Eluting Stents products under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Drug Eluting Stents and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Drug Eluting Stents under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Drug Eluting Stents (DES) - Pipeline Review, 2015
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 14
Introduction 15
Drug Eluting Stents (DES) Overview 15
Products under Development 16
Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 16
Drug Eluting Stents (DES) - Pipeline Products by Segment 17
Drug Eluting Stents (DES) - Pipeline Products by Territory 18
Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path 19
Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date 20
Drug Eluting Stents (DES) - Ongoing Clinical Trials 21
Drug Eluting Stents (DES) - Pipeline Products under Development by Companies 22
Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development 22
Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 24
Drug Eluting Stents (DES) Companies and Product Overview 27
Abbott Vascular Inc. Company Overview 27
Abbott Vascular Inc. Pipeline Products and Ongoing Clinical Trials Overview 27
Abbott Vascular Inc. - Ongoing Clinical Trials Overview 29
Absorb Bioresorbable Vascular Scaffold Clinical Trial Details 31
AlviMedica Medical Technologies Inc. Company Overview 40
AlviMedica Medical Technologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 40
AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview 42
Cre8 DES Clinical Trial Details 43
Amaranth Medical, Inc. Company Overview 45
Amaranth Medical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 45
Amaranth Medical, Inc. - Ongoing Clinical Trials Overview 47
FORTITUDE Scaffold Ongoing Clinical Trial Details 48
Next Generation FORTITUDE Scaffold Ongoing Clinical Trial Details 49
Arterius Ltd Company Overview 50
Arterius Ltd Pipeline Products and Ongoing Clinical Trials Overview 50
Biosensors International Group, Ltd. Company Overview 51
Biosensors International Group, Ltd. Pipeline Products and Ongoing Clinical Trials Overview 51
Biosensors International Group, Ltd. - Ongoing Clinical Trials Overview 53
BioFreedom Drug Coated Stent Clinical Trial Details 54
Excel II DES Ongoing Clinical Trial Details 55
BioSurfaces, Inc. Company Overview 56
BioSurfaces, Inc. Pipeline Products and Ongoing Clinical Trials Overview 56
Biotronik SE and Co. KG Company Overview 57
Biotronik SE and Co. KG Pipeline Products and Ongoing Clinical Trials Overview 57
Biotronik SE and Co. KG - Ongoing Clinical Trials Overview 60
Orsiro Hybrid Drug Eluting Stent Clinical Trial Details 61
Boston Scientific Corporation Company Overview 62
Boston Scientific Corporation Pipeline Products and Ongoing Clinical Trials Overview 62
Boston Scientific Corporation - Ongoing Clinical Trials Overview 65
SYNERGY Everolimus-Eluting Stent System Clinical Trial Details 66
CARDIONOVUM GmbH Company Overview 69
CARDIONOVUM GmbH Pipeline Products and Ongoing Clinical Trials Overview 69
CID S.r.l. Company Overview 71
CID S.r.l. Pipeline Products and Ongoing Clinical Trials Overview 71
Contego Medical, LLC Company Overview 73
Contego Medical, LLC Pipeline Products and Ongoing Clinical Trials Overview 73
DISA Vascular (Pty) Ltd. Company Overview 74
DISA Vascular (Pty) Ltd. Pipeline Products and Ongoing Clinical Trials Overview 74
Elixir Medical Corporation Company Overview 75
Elixir Medical Corporation Pipeline Products and Ongoing Clinical Trials Overview 75
Elixir Medical Corporation - Ongoing Clinical Trials Overview 80
DESyne BD Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details 81
DESyne Nx Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details 82
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System Ongoing Clinical Trial Details 83
Envision Scientific Pvt. Ltd Company Overview 84
Envision Scientific Pvt. Ltd Pipeline Products and Ongoing Clinical Trials Overview 84
Eurocor GmbH Company Overview 85
Eurocor GmbH Pipeline Products and Ongoing Clinical Trials Overview 85
HangZhou HuaAn Biotechnology Co.,Ltd Company Overview 87
HangZhou HuaAn Biotechnology Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 87
Icon Interventional Systems, Inc. Company Overview 88
Icon Interventional Systems, Inc. Pipeline Products and Ongoing Clinical Trials Overview 88
ICON Medical Corp. Company Overview 89
ICON Medical Corp. Pipeline Products and Ongoing Clinical Trials Overview 89
InspireMD, Inc. Company Overview 90
InspireMD, Inc. Pipeline Products and Ongoing Clinical Trials Overview 90
IRAMED GmbH Company Overview 92
IRAMED GmbH Pipeline Products and Ongoing Clinical Trials Overview 92
Lepu Medical Technology (Beijing) Co., Ltd. Company Overview 95
Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 95
Lepu Medical Technology (Beijing) Co., Ltd. - Ongoing Clinical Trials Overview 97
Nano+ Stent Ongoing Clinical Trial Details 98
Medinol Ltd. Company Overview 99
Medinol Ltd. Pipeline Products and Ongoing Clinical Trials Overview 99
Medinol Ltd. - Ongoing Clinical Trials Overview 100
NIRsupreme Ridaforolimus-Eluting Coronary Stent System Clinical Trial Details 101
Medtronic plc Company Overview 102
Medtronic plc Pipeline Products and Ongoing Clinical Trials Overview 102
Meril Life Sciences Pvt. Ltd. Company Overview 104
Meril Life Sciences Pvt. Ltd. Pipeline Products and Ongoing Clinical Trials Overview 104
Meril Life Sciences Pvt. Ltd. - Ongoing Clinical Trials Overview 108
BioMime Ongoing Clinical Trial Details 109
Micell Technologies, Inc. Company Overview 110
Micell Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 110
Minvasys Company Overview 112
Minvasys Pipeline Products and Ongoing Clinical Trials Overview 112
NanoCoeur, Inc. Company Overview 114
NanoCoeur, Inc. Pipeline Products and Ongoing Clinical Trials Overview 114
Northwestern University Company Overview 115
Northwestern University Pipeline Products and Ongoing Clinical Trials Overview 115
OrbusNeich Company Overview 117
OrbusNeich Pipeline Products and Ongoing Clinical Trials Overview 117
OrbusNeich - Ongoing Clinical Trials Overview 119
COMBO Dual Therapy Stent Clinical Trial Details 120
REVA Medical, Inc. Company Overview 122
REVA Medical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 122
Sino Medical-Device Technology Co., Ltd. Company Overview 125
Sino Medical-Device Technology Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 125
Stentys, SA Company Overview 126
Stentys, SA Pipeline Products and Ongoing Clinical Trials Overview 126
Svelte Medical Systems, Inc. Company Overview 128
Svelte Medical Systems, Inc. Pipeline Products and Ongoing Clinical Trials Overview 128
Tepha, Inc. Company Overview 130
Tepha, Inc. Pipeline Products and Ongoing Clinical Trials Overview 130
Terumo Corporation Company Overview 131
Terumo Corporation Pipeline Products and Ongoing Clinical Trials Overview 131
Terumo Corporation - Ongoing Clinical Trials Overview 134
Ultimaster Ongoing Clinical Trial Details 135
Tryton Medical, Inc. Company Overview 136
Tryton Medical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 136
University of Strathclyde Company Overview 138
University of Strathclyde Pipeline Products and Ongoing Clinical Trials Overview 138
VasoTech Inc. Company Overview 140
VasoTech Inc. Pipeline Products and Ongoing Clinical Trials Overview 140
Xenogenics Corporation Company Overview 142
Xenogenics Corporation Pipeline Products and Ongoing Clinical Trials Overview 142
Zorion Medical Company Overview 144
Zorion Medical Pipeline Products and Ongoing Clinical Trials Overview 144
Drug Eluting Stents (DES)- Recent Developments 145
Mar 02, 2015: Tryton Medical Announces Publication of Data from Pivotal Trial for Tryton Side Branch Stent in Journal of American College of Cardiology 145
Feb 23, 2015: REVA Bioresorbable Program Update at CRT Conference 146
Feb 19, 2015: BIOTRONIK Advances Clinical Evaluation of Latest Generation DREAMS, World's First Bioabsorbable Magnesium Scaffold 146
Feb 13, 2015: COMBO Dual Therapy Stent - Three-year Data featured at JIM 2015 147
Feb 12, 2015: Svelte Medical Systems and ASAHI INTECC Announce Manufacturing and Co-Branding Agreements 148
Feb 12, 2015: Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2015 148
Feb 09, 2015: LEADERS Free Japan Trial Completes Enrollment 150
Feb 04, 2015: Micell Technologies MiStent SES Now Commercially Available in Europe 151
Feb 04, 2015: BIOTRONIK Announces Completion of Patient Enrollment in BIOFLOW-IV Study Evaluating Safety and Efficacy of Orsiro 152
Jan 29, 2015: Abbott Reports Fourth-Quarter 2014 Results 152
Jan 23, 2015: MicroPort Receives CE Mark Approval for Firehawk 155
Jan 20, 2015: Mr. Aurelio Sahagun Promoted to COO of MicroPort Orthopedics 156
Jan 16, 2015: Eurocor Receives CE Mark Approval for E-Magic Plus SES 156
Jan 06, 2015: Biosensors Announces CTO'S Retirement 157
Jan 05, 2015: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Cordis 157
Jan 04, 2015: Firehawk Gains CFDA Approval to Offer More Specifications 157
Dec 11, 2014: COMBO Dual Therapy Stent Healing Benefits Highlighted at GulfPCR-GIM 2014 157
Dec 03, 2014: REVA Implants First Patients With Fantom Scaffold 158
Dec 02, 2014: Terumo receives CE Mark approval for the line extension on Drug-eluting Stent, Ultimaster to advance the treatment of coronary artery disease 159
Nov 19, 2014: New Data From EVOLVE Clinical Program Demonstrate SYNERGY Bioabsorbable Polymer Stent Meets Key Performance Endpoints 159
Nov 12, 2014: Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2015 160
Nov 05, 2014: ClearStream Technologies Expands Enniscorthy Facility 162
Nov 04, 2014: Boston Scientific To Host And Webcast Investor Event 163
Nov 03, 2014: Micell Technologies Announces Plans for MiStent SES Commercial Launch 163
Nov 03, 2014: Medtronic Secures CE Mark For Resolute Onyx Drug-eluting Stent 164
Nov 03, 2014: STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent 164
Oct 27, 2014: STENTYS' Sirolimus-Eluting Stent Receives CE Marking 165
Oct 20, 2014: Boston Scientific Initiates Study Of Promus PREMIER Coronary Stent System In Underserved Patient Populations 166
Oct 17, 2014: COMBO Dual Therapy Stent - A Long-term Solution to Vessel Restoration 167
Oct 10, 2014: BIOTRONIK to Offer New Treatment Options in France with Release of Orsiro Drug-Eluting Stent 167
Sep 18, 2014: Latest Data Shows OrbusNeich's COMBO Dual Therapy Stent has Excellent Healing Benefits 168
Sep 18, 2014: World's First Integrated Delivery System Meets All Endpoints in the Direct II Randomized, Controlled Drug-Eluting Coronary Stent Study 169
Sep 16, 2014: REVA Presents Fantom Scaffold Program at TCT 2014 Conference 170
Sep 16, 2014: Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014 170
Sep 16, 2014: Amaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting Scaffold 171
Sep 15, 2014: Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device 172
Sep 14, 2014: ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 173
Sep 10, 2014: Tryton Medical Enrolls First U.S. Patient in the EXTENDED ACCESS Registry 174
Sep 10, 2014: Global Bifurcation Leader Tryton Medical Announces Events at TCT 2014 175
Sep 08, 2014: Elixir Medical Announces Schedule of Programs for TCT 2014 176
Sep 04, 2014: Initial Patient Enrolled in BioFreedom USA: First Major American Trial for Biosensors 177
Sep 03, 2014: STENTYS Reaches 10,000 Self-Apposing Stent implantations 178
Sep 01, 2014: BIOSCIENCE Trial Further Confirms Orsiro as Best in Class 178
Sep 01, 2014: Biosensors Welcomes New CEO 179
Aug 06, 2014: Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015 179
Jul 28, 2014: Tryton Medical Enrolls First Patient in the EXTENDED Access Registry 181
Jul 16, 2014: First patient enrollment in MASCOT registry represents major milestone for COMBO Dual Therapy Stent and OrbusNeich's clinical program 182
Jul 10, 2014: Abbott Builds Long Term Commitment In China 182
Jul 09, 2014: Micell Technologies Adds to Portfolio of Intellectual Property Protection 183
Jul 09, 2014: STENTYS Expands Marketing of the Self-Apposing Stent in South America 184
Jun 24, 2014: Abbott Announces Job Reductions At Lake County Headquarters In US 184
Jun 17, 2014: Biosensors Leaders Free Japan Trial Enrolls First Patient 185
Jun 12, 2014: First Patient Enrolled in Investigator Initiated REDUCE Study 185
Jun 02, 2014: Stentys Completes Acquisition of Cappella Peel Away from Cappella for USD1.4 Million 186
May 29, 2014: Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study 186
May 28, 2014: Biosensors Reports Financial Results for Fiscal Year 2014 187
May 28, 2014: Biosensors Announces Appointment of New CEO 189
May 27, 2014: STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference 189
May 23, 2014: OrbusNeich Releases Long-term Data for World's First and Only Dual Therapy Stent 190
May 23, 2014: Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014 191
May 23, 2014: Elixir Medical Announces Clinical Trial Results of DESyne BD Novolimus Eluting Coronary Stent System at EuroPCR 192
May 23, 2014: Elixir Medical Announces Results for CE mark-approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System at EuroPCR 192
May 23, 2014: Elixir Medical Announces Outstanding Long-Term Clinical Results at EuroPCR for World's Broadest Portfolio of Three CE Mark-Approved Novolimus Eluting Coronary Intervention Systems 193
May 22, 2014: REVA Holds Sponsored Symposium at EuroPCR 194
May 22, 2014: Complex Lesion BIOFLOW-III Subgroup Analyses Further Support Top Performance of BIOTRONIK Orsiro 194
May 21, 2014: Successful Live Case Demonstration of Elixir Medical's CE Mark-Approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR 195
May 21, 2014: Boston Scientific Reports Strong Performance Data For SYNERGY Stent System 196
May 21, 2014: Biosensors Leaders Free Patient Population Data Presented at EuroPCR Enrollment Now Complete 196
May 21, 2014: Small Vessel BIOFLOW-II Subgroup Analyses Demonstrate Top Performance of BIOTRONIK Orsiro 197
May 20, 2014: STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients 198
May 15, 2014: Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014 198
May 14, 2014: Elixir Medical to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR 199
May 13, 2014: Elixir Medical's DESolve 100 Novolimus Eluting Coronary Scaffold System Gets CE Mark 200
May 06, 2014: STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis 201
May 05, 2014: USFDA Grants IDE Approval For Biosensors' BioFreedom US Feasibility Trial 202
May 01, 2014: Boston Scientific Launches Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan 203
Apr 29, 2014: STENTYS' Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology 203
Apr 28, 2014: MicroPort Released New Products to its Nationwide Distributors 204
Apr 10, 2014: Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United States, Japan and China 204
Mar 28, 2014: Patient Enrollment Completed in Multicenter European REMEDEE Registry of OrbusNeich's COMBO Dual Therapy Stent 205
Mar 27, 2014: Arterial Remodeling Technologies Enters Into Co-Development Agreement With Terumo For Bioresorbable Scaffold 205
Appendix 207
Methodology 207
Keywords: 209
About GlobalData 210
Contact Us 210
Disclaimer 210

List of Tables
List of Tables
Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 16
Drug Eluting Stents (DES) - Pipeline Products by Segment 17
Drug Eluting Stents (DES) - Pipeline Products by Territory 18
Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path 19
Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date 20
Drug Eluting Stents (DES) - Ongoing Clinical Trials 21
Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development 22
Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 24
Abbott Vascular Inc. Pipeline Products and Ongoing Clinical Trials Overview 27
Absorb Bioresorbable Vascular Scaffold - Product Status 27
Absorb Bioresorbable Vascular Scaffold - Product Description 28
XIENCE Thinman DES - Product Status 28
XIENCE Thinman DES - Product Description 28
Abbott Vascular Inc. - Ongoing Clinical Trials Overview 29
Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population 31
Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, The Everolimus Eluting Bioresorbable Vascular Scaffold In The Treatment Of Subjects With De Novo Native Coronary Artery Lesions 31
Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions 32
Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of AVJ-301 (Absorb BVS), The Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population 32
Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects with Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions: ABSORB II Randomized Controlled Trial 33
Absorb Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation 33
Absorb Bioresorbable Vascular Scaffold - A Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study) Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial) 34
Absorb Bioresorbable Vascular Scaffold - A Post-market Registry of Patients with de Novo Lesions in Previously Untreated Vessels Treated with Absorb BVS 34
Absorb Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers 35
Absorb Bioresorbable Vascular Scaffold - An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS): ABSORB FIRST Registry 35
Absorb Bioresorbable Vascular Scaffold - Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction 36
Absorb Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: a Multi-modality, Multi-specialty Collaborative Study (PERFECT Program) 36
Absorb Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study 37
Absorb Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis 37
Absorb Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study 38
Absorb Bioresorbable Vascular Scaffold - Intracoronary Scaffold Assessment a Randomised Evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI): A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction 38
Absorb Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI) 39
AlviMedica Medical Technologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 40
Coracto Rapamycin-Eluting Coronary Stent - Product Status 40
Coracto Rapamycin-Eluting Coronary Stent - Product Description 41
Cre8 DES - Product Status 41
Cre8 DES - Product Description 41
AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview 42
Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions 43
Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions 43
Cre8 DES - A Prospective, Single Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8 44
Amaranth Medical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 45
FORTITUDE Scaffold - Product Status 45
FORTITUDE Scaffold - Product Description 45
Next Generation FORTITUDE Scaffold - Product Status 46
Next Generation FORTITUDE Scaffold - Product Description 46
Amaranth Medical, Inc. - Ongoing Clinical Trials Overview 47
FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial 48
Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold 49
Arterius Ltd Pipeline Products and Ongoing Clinical Trials Overview 50
Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status 50
Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description 50
Biosensors International Group, Ltd. Pipeline Products and Ongoing Clinical Trials Overview 51
BioFreedom Drug Coated Stent - Product Status 51
BioFreedom Drug Coated Stent - Product Description 52
Excel II DES - Product Status 52
Excel II DES - Product Description 52
Biosensors International Group, Ltd. - Ongoing Clinical Trials Overview 53
BioFreedom Drug Coated Stent - A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent versus the Gazelle Bare Metal Stent in Patients with High Risk of Bleeding 54
BioFreedom Drug Coated Stent - To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom BA9 Drug Coated Coronary Stent in Patients with Native, de Novo Coronary Artery Disease 54
Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial) 55
BioSurfaces, Inc. Pipeline Products and Ongoing Clinical Trials Overview 56
Drug-Eluting Stent Jacket - Product Status 56
Drug-Eluting Stent Jacket - Product Description 56
Biotronik SE and Co. KG Pipeline Products and Ongoing Clinical Trials Overview 57
DREAMS - Product Status 57
DREAMS - Product Description 58
DREAMS 2 - Product Status 58
DREAMS 2 - Product Description 58
Orsiro Hybrid Drug Eluting Stent - Product Status 59
Orsiro Hybrid Drug Eluting Stent - Product Description 59
Biotronik SE and Co. KG - Ongoing Clinical Trials Overview 60
Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 61
Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III United Kingdom Satellite 61
Boston Scientific Corporation Pipeline Products and Ongoing Clinical Trials Overview 62
Next Generation SYNERGY - Product Status 62
Next Generation SYNERGY - Product Description 63
SYNERGY Everolimus-Eluting Stent System - Product Status 63
SYNERGY Everolimus-Eluting Stent System - Product Description 64
Boston Scientific Corporation - Ongoing Clinical Trials Overview 65
SYNERGY Everolimus-Eluting Stent System - A Prospective Optical Coherence Tomography (OCT) Study on Coronary Vessel Wall Response to Stent Eluting Everolimus from a Biodegradable Polymer (EES SYNERGY) Compared with Stent Eluting Zotarolimus from a Durable Polymer (ZES, RESOLUTE Integrity) 66
SYNERGY Everolimus-Eluting Stent System - A Single-Arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating 66
SYNERGY Everolimus-Eluting Stent System - Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax) to the Drug (Everolimus) -Eluting Stent (Synergy) in Acute Coronary Syndrome 67
SYNERGY Everolimus-Eluting Stent System - Conventional Antegrade Vs Sub-intimal Synergy Stenting in Chronic Total Occlusions 67
SYNERGY Everolimus-Eluting Stent System - Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population 67
SYNERGY Everolimus-Eluting Stent System - Randomized Clinical Comparison of Everolimus-eluting SYNERGY and Biolimus-eluting BioMatrix NeoFlex Coronary Stents in Non-selected Patients with Ischemic Heart Disease 68
SYNERGY Everolimus-Eluting Stent System - Randomized Comparison of the Biolimus-eluting Biomatrix Neoflex og Everolimus-eluting SYNERGY Stents in All-comer Patients with Ischemic Heart Disease: The OCT SORT-OUT VIII 68
CARDIONOVUM GmbH Pipeline Products and Ongoing Clinical Trials Overview 69
ReNATURAL (M) - Product Status 69
ReNATURAL (M) - Product Description 69
ReNATURAL (P) - Product Status 70
ReNATURAL (P) - Product Description 70
CID S.r.l. Pipeline Products and Ongoing Clinical Trials Overview 71
Janus Flex - Product Status 71
Janus Flex - Product Description 72
Optima Jet - Product Status 72
Optima Jet - Product Description 72
Contego Medical, LLC Pipeline Products and Ongoing Clinical Trials Overview 73
CORGUARD - Product Status 73
CORGUARD - Product Description 73
DISA Vascular (Pty) Ltd. Pipeline Products and Ongoing Clinical Trials Overview 74
Stellium Stent - Product Status 74
Stellium Stent - Product Description 74
Elixir Medical Corporation Pipeline Products and Ongoing Clinical Trials Overview 75
DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status 75
DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description 76
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status 76
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description 76
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status 77
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description 77
DESyne BD Novolimus Eluting Coronary Stent System - Product Status 77
DESyne BD Novolimus Eluting Coronary Stent System - Product Description 78
DESyne Nx Novolimus Eluting Coronary Stent System - Product Status 78
DESyne Nx Novolimus Eluting Coronary Stent System - Product Description 78
Myolimus Eluting Coronary Stent - Durable Polymer - Product Status 79
Myolimus Eluting Coronary Stent - Durable Polymer - Product Description 79
Elixir Medical Corporation - Ongoing Clinical Trials Overview 80
DESyne BD Novolimus Eluting Coronary Stent System - Post Marketing Study of the Elixir Desyne Novolimus Eluting Coronary Stent System and the Desyne BD Novolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions 81
DESyne Nx Novolimus Eluting Coronary Stent System - Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study 82
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Post-market Evaluation of Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System in the Treatment of Patients with De Novo Native Coronary Artery Lesions 83
Envision Scientific Pvt. Ltd Pipeline Products and Ongoing Clinical Trials Overview 84
FOCUS np - Product Status 84
FOCUS np - Product Description 84
Eurocor GmbH Pipeline Products and Ongoing Clinical Trials Overview 85
Genius TAXCOR - Product Status 85
Genius TAXCOR - Product Description 86
HangZhou HuaAn Biotechnology Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 87
Xinsorb BRS - Product Status 87
Xinsorb BRS - Product Description 87
Icon Interventional Systems, Inc. Pipeline Products and Ongoing Clinical Trials Overview 88
Biosorb - Product Status 88
Biosorb - Product Description 88
ICON Medical Corp. Pipeline Products and Ongoing Clinical Trials Overview 89
Nuloy DES - Product Status 89
Nuloy DES - Product Description 89
InspireMD, Inc. Pipeline Products and Ongoing Clinical Trials Overview 90
MGuard Drug Eluting Stent - Product Status 90
MGuard Drug Eluting Stent - Product Description 91
IRAMED GmbH Pipeline Products and Ongoing Clinical Trials Overview 92
EasyRap - Product Status 92
EasyRap - Product Description 92
FlexyRap - Product Status 93
FlexyRap - Product Description 93
MovyTax - Product Status 93
MovyTax - Product Description 94
Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 95
Nano+ Stent - Product Status 95
Nano+ Stent - Product Description 96
Lepu Medical Technology (Beijing) Co., Ltd. - Ongoing Clinical Trials Overview 97
Nano+ Stent - Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Lesion: A Optical Coherent Tomography Prospective, Multicenter Study 98
Medinol Ltd. Pipeline Products and Ongoing Clinical Trials Overview 99
NIRsupreme Ridaforolimus-Eluting Coronary Stent System - Product Status 99
NIRsupreme Ridaforolimus-Eluting Coronary Stent System - Product Description 99
Medinol Ltd. - Ongoing Clinical Trials Overview 100
NIRsupreme Ridaforolimus-Eluting Coronary Stent System - BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) EUropean Angiography Study 101
NIRsupreme Ridaforolimus-Eluting Coronary Stent System - BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) in Coronary Stenosis Trial 101
Medtronic plc Pipeline Products and Ongoing Clinical Trials Overview 102
Next Generation Coronary Stent - Product Status 102
Next Generation Coronary Stent - Product Description 103
Resolute Onyx - Product Status 103
Resolute Onyx - Product Description 103
Meril Life Sciences Pvt. Ltd. Pipeline Products and Ongoing Clinical Trials Overview 104
BioMime - Product Status 104
BioMime - Product Description 105
BIOMIME AURA - Product Status 105
BIOMIME AURA - Product Description 105
MeRes - Product Status 106
MeRes - Product Description 106
MITSU - Product Status 107
M

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
European Market Report for Dialysis Catheters 2017 - MedCore

European Market Report for Dialysis Catheters 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The European market for dialysis catheters comprises the acute hemodialysis, chronic hemodialysis and peritoneal dialysis catheter segments. The chronic hemodialysis catheter market is segmented ...

Vascular Access Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Vascular Access Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Vascular Access Devices Market: Scope and Methodology Vascular access devices are medical devices used to obtain access to the bloodstream, and are hollow and flexible tubes made of latex, silicone, and ...

Czech Republic Interventional Cardiology Market Outlook to 2022

Czech Republic Interventional Cardiology Market Outlook to 2022

  • $ 4995
  • Industry report
  • September 2016
  • by Global Data

Czech Republic Interventional Cardiology Market Outlook to 2022 Summary GlobalData’s new report, Czech Republic Interventional Cardiology Market Outlook to 2022, provides key market data on the Czech ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.